Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + nintedanib
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **bevacizumab**, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing the formation of new blood vessels that tumors need to grow. **Nintedanib** is a triple angiokinase inhibitor targeting VEGF, fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) pathways, which are involved in angiogenesis and tumor growth. The combination aims to enhance anti-tumor activity by overcoming resistance to anti-VEGF therapies.
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)LYN (LYN proto-oncogene, Src family tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)LCK (Proto-oncogene tyrosine-protein kinase Lck)
Beyond the preview
Go deeper on bevacizumab + nintedanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + nintedanib.